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1. Introduction 
Twenty-six million American adults have Chronic Kidney Disease (CKD). Chronic Kidney 
Disease is defined as kidney damage for 3 or more months with or without decreased GFR. 
Chronic Kidney Disease is divided into five stages, from Stage 1 to Stage 5. End-Stage renal 
disease is the 5th stage of CKD when dialysis is needed to sustain life. Sleep disorders are 
common and under recognized in advanced stages of Chronic Kidney Disease. Sleep disorders 
affect the quality of life and may also increase cardiovascular morbidity and mortality.  
Subjective sleep complaints are reported by more than 50% of patients on Hemodialysis 
(HD) (1). Common organic sleep disorders in patients with CKD include Sleep Apnea 
Syndrome (SAS), Periodic Limb Movement Disorder (PLMD) and Restless Leg Syndrome 
(RLS). These disorders are more common in the dialysis population than in the general 
population. When dialysis patients with a sleep disorders were studied objectively in sleep 
laboratory, 53% to 75% were found to have sleep apnea, which is higher than general 
population (2-4%) (2). Sleep disorders in CKD patients have been linked to increased 
incidences of cardiovascular disease including coronary artery disease, left ventricular 
hypertrophy and hypertension. (3, 4, 5, 6). Heart disease is the major cause of death in 
patients with CKD (www.kidney.org). In fact most patients who have advanced CKD and 
are not on dialysis are more likely to die from heart disease before they start dialysis. 
Daytime somnolence resulting from sleep disorders may lead to diminished quality of life 
and cognition (7, 8).PLMD is associated with increased mortality in patients with ESRD. 
(49). Early diagnosis and treatment may improve quality of life. 
2. Subjective complaints in dialysis patients  
Subjective sleep complaints are common in dialysis patients and include difficulty initiating 
and maintaining sleep, problems with restless, jerking legs, and/or day time sleepiness. 
Sleep disorders are very inconvenient for the patients and affect their activities of daily 
living. Most patients believe that relief of these symptoms would improve subjective quality 
of life. A large number of dialysis patients take sleep-inducing medications. Sleep 
complaints are more common in elderly patients on dialysis than in younger patients and 
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male patients are more likely to have sleep complaints than women (10). Caucasian patients 
have a higher prevalence of restless legs syndrome than African American (1, 10). Subjective 
complaints are also high in patients with increased caffeine intake, pruritis, bone pain, 
cigarette use, and premature discontinuation of dialysis (1). As in general population, 
increased stress, anxiety, depression, and worry are also associated with poor subjective 
sleep quality in dialysis patients (10-12).  
3. Factors contributing to sleep disturbances (Figure 1) 
No consistent relationship has been detected between subjective sleep complaints of poor 
sleep and Blood Urea Nitrogen (BUN), Creatinine, or Kt/V (see glossary) (1, 11, & 13). 
Anemia has been associated with complaints of poor sleep with improvement after 
treatment with recombinant erythropoietin (14). Mild hypercalecmia has also been 
associated with increased frequency of subjective insomnia (15). Frequent napping during 
day time dialysis may also be a factor which contributes to fragmented sleep at night. 
 
Fig. 1. Factors associated with sleep disturbances. 
Nocturia, one of the earliest symptoms of kidney disease may also lead to reduced sleep due 
to frequent awakening. Untreated sleep apnea has also been linked to nocturia. Most of the 
awakenings attributed to nocturia by patients are attributable to sleep disorders, particularly 
sleep apnea (63). 
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4. Changes in sleep architecture 
Nocturnal sleep of patients on dialysis is short and fragmented with total sleep time ranging 
between 260 and 360 minutes. Sleep efficiency is between 66% and 85% with a large amount 
of wakeful time (77-135 min), and numerous arousals (25-30/h of sleep) (16-18). Patients 
have increased patterns of Stage I and Stage II sleep, decreased slow wave (deep sleep), and 
REM sleep (17, 18). Thus dialysis patients have both reduced quantity and quality of sleep. 
Changes in sleep patterns in advanced CKD patients who are not on dialysis are similar to 
patients on dialysis (21) 
5. Sleep Apnea Syndrome (SAS) 
Sleep apnea is classified as obstructive (OSA) due to intermittent closure of the upper 
airway or central due to intermittent loss of respiratory drive or both (mixed). More than 
50% of patients with ESRD have sleep apnea (7, 19). Prevalence appears to be similar in 
advanced CKD patients who are not on dialysis and those treated with peritoneal or 
hemodialysis (7, 20). Sleep Disordered Breathing (SDB) is observed with similar frequency 
in dialysis dependent and dialysis independent CKD patients. Sleep apnea in CKD patients 
is more frequently obstructive (21). 
6. Pathogenesis-figure 2 
Sleep apnea in patients with ESRD is mostly obstructive but several observers have reported 
features of both obstructive and central sleep apnea (16,31). Sleep apnea is caused by both 
impaired central ventilatory control and upper air way occlusion during sleep. Enhanced 
ventilatory sensitivity to hypercapnea correlates with apnea severity (22). Conversion from 
conventional Hemodialysis (CHD) to nocturnal Hemodialysis (NHD) has been associated with 
reduced severity of sleep apnea due to reduction in ventilatory sensitivity to hypercapnea(31). 
Upper airway occlusion can be caused by fluid overload and interstitial edema in the upper air 
way (23). Displacement of fluids from the lower limbs increases neck circumference and 
pharyngeal resistance and reduces upper air way cross sectional area, contributing to the 
pathogenesis of obstructive sleep apnea (OSA). Pharyngeal cross sectional area in patients on 
CHD was smaller than the control, suggesting that this may predispose to upper airway 
occlusion during sleep (22). Conversion from CHD to NHD is associated with an increase in 
pharyngeal cross sectional area, possibly due to improve fluid removal(31). Conversion from 
continuous ambulatory peritoneal dialysis (CAPD) to nocturnal peritoneal dialysis has been 
shown to reduce the frequency of sleep apnea (24). Upper airway dilator muscle dysfunction 
due to neuropathy or myopathy associated with chronic uremia or the underlying cause of 
renal disease such as diabetes mellitus can cause narrowing of pharyngeal muscles (31). There 
could also be some role for oxidative stress, inflammatory cytokines and middle molecules, all 
elevated in ESRD in the development of ventilatory instability and or upper airway occlusion, 
but this has not been established (66). 
The apnea –hypopnea index (AHI) is an index used to assess the severity of sleep apnea 
based on the total number of complete cessations (apnea) and partial obstructions 
(hypopnea) of breathing occurring per hour of sleep found during polysomnography. 
Patients with advanced CKD not on dialysis who are non-diabetic are predisposed to more 
severe AHI as compared to patients with less advanced CKD (25). In patients with diabetes 
no such association was found probably due to the fact that diabetes itself may be an  
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Fig. 2. Pathogenesis of sleep Apnea Syndrome (SAS). 
overriding  factor for the development of sleep apnea (25). It was also found that AHI index 
correlated weakly with urea level in all patients, but not with creatinine clearance. 
Obesity is not required for ESRD patients to develop sleep apnea. Snoring is less intense in 
patients with CKD who have sleep apnea than in patients with sleep apnea with normal 
renal function (67). 
7. Clinical significance 
Sleep apnea worsens the symptoms of CKD such as daytime fatigue, sleepiness, and 
impaired neurocognitive function. Hypoxemia during sleep is associated with nocturnal 
hypertension, left ventricular hypertrophy, impaired sympathovagal balance, and increased 
risk of cardiovascular complications including death (68-69). Sleep apnea may exacerbate 
the infectious complications common in ESRD patients because sleep disruption and 
deprivation degrade immune function (26). Severe sleep apnea is an independent predictor 
of graft loss among female kidney transplant patients (27). 
8. Diagnosis 
Subjective sleepiness can be assessed with a number of simple scales, such as the Epworth 
Sleepiness Scale (ESS) or the Stanford Sleepiness Scale. The ESS is a self-administered 
SAS 
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questionnaire with 8 questions and is more commonly used. It provides a measure of a 
person’s general level of daytime sleepiness, or their average sleep propensity in daily life 
.The ESS asks people to rate, on a 4-point scale (0 – 3), their usual chances of dozing off or 
falling asleep in 8 different situations or activities that most people engage in as part of their 
daily lives. The total ESS score is the sum of 8 item-scores and can range between 0 and 
24.The higher the score, the higher the person’s level of daytime sleepiness. Most people can 
answer the ESS, without assistance, in 2 or 3 minutes. (www.sleepfoundation.org). 
Although the characteristic features of sleep apnea may be absent, a history of snoring, 
witnessed apnea during sleep, and day time sleepiness are suggestive of sleep apnea. 
Objective diagnostic testing includes home ambulatory monitoring which records air flow, 
snoring, respiratory movement, oxygen saturation, and heart rate. 
Polysomnography (PSG), also known as a sleep study is a nocturnal, laboratory- test used in 
the diagnosis of Sleep Apnea Syndrome (SAS). It is often considered the standard for 
diagnosing OSAS, determining the severity of the disease, and evaluating various other 
sleep disorders that can exist with or without OSAS. PSG consists of a simultaneous 
recording of multiple physiologic parameters related to sleep and wakefulness. It generally 
includes monitoring of the patient's airflow through the nose and mouth, blood pressure, 
heartbeat as measured by an electrocardiograph, blood oxygen level,EEG wave patterns, eye 
movements(EOG), and the movements of respiratory muscles and limbs(EMG). 
Polysomnography can be performed in a sleep laboratory or center and includes 
comprehensive monitoring of respiration, sleep stages and leg movements. 
Polysomnography is used to quantify the Apnea-Hypopnea Index (AHI). AHI is an index 
used to assess the severity of sleep apnea based on the total number of complete cessations 
(apnea) and partial obstructions (hypopnea) of breathing occurring per hour of sleep. These 
pauses in breathing must last for at least 10 seconds and be associated with a 3% or greater 
decrease in oxygenation of the blood. To determine AHI, add the total number of apnea 
events, plus hypopnea events and divide by the total number of minutes of actual sleep 
time, then multiply by 60.For example: 
Apnea + Hypopnea divided by actual sleep time, then multiply by 60 
200 apneas, 200 Hypopneas (400 Total Events) 
420 Minutes Actual Sleep Time (7 hours x 60) 
Divide 400 by 420 = .95 x 60 = 57 AHI (Severe OSA) 
In general, the AHI can be used to classify the severity of disease (mild 5-15, moderate 16-30, 
and severe greater than 30).  
Multiple Sleep Latency Test (MSLT) and the Maintenance of Wakefulness Test (MWT) can 
be considered for the evaluation of day time sleepiness. MSLT is used to measure the time 
elapsed from the start of a daytime nap period to the first signs of sleep, called sleep latency. 
The test is based on the idea that the sleepier people are, the faster they will fall asleep. The 
MWT is a daytime polysomnographic procedure which quantifies wake tendency by 
measuring the ability to remain awake during sleep conducive circumstances. The test 
isolates a person from factors that can influence sleep such as temperature, light, and noise. 
Furthermore, the patient is also advised to not take any hypnotics, drink alcohol, or smoke 
before or during the test. After allowing the patient to lie down on the bed, the time between 
lying down and falling asleep is measured and used to determine one’s daytime sleepiness. 
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Sleep apnea should be treated if the patient has symptoms such as fragmented sleep and 
day time sleepiness or significant oxygen desaturation. In patients without sleep related 
symptoms who have PSG suggestive of severe sleep apnea, consideration should be given to 
treat patients with severe disease (Apnea/hypopnea index >30), since sleep apnea of this 
severity has been associated with increased cardiovascular morbidity and mortality. Sleep 
apnea should also be treated if it is exacerbating co-existing medical condition such as 
hypertension, myocardial ischemia, and respiratory failure or nocturnal hypoxemia. 
Management of sleep apnea includes treatment of any underlying medical conditions such 
as obesity or hypothyroidism, correction of aggravating factors such as use of alcohol or 
sedatives close to the bedtime. Continuous Positive Airway Pressure (CPAP) is a method of 
respiratory ventilation used primarily in the treatment of sleep apnea . The CPAP machine 
delivers a stream of compressed air via a hose to a nose mask, full-face mask, or hybrid, 
splinting the airway (keeping it open under air pressure) so that unobstructed breathing 
becomes possible, therefore reducing and/or preventing apneas and hypopnea. Pressman 
and Benz first reported in 1993 that CPAP improves both OSA and central apnea in ESRD 
patients, suggesting that CPAP eliminates the repetitive cyclical pattern of apnea followed 
by deep breathing, then followed by another central apnea.(28) The degree of hypopnea 
following apnea may be a function of the magnitude of respiratory drive necessary to 
overcome upper air way occlusion at the end of apnea. By preventing air way collapse, 
CPAP probably eliminates the deep breathing that results in hyperventilation and then 
lowered respiratory drive, thus setting the stage for next central sleep apnea. Also high 
levels of CPAP are successful in treatment of central sleep apnea due to the fact that central 
sleep apnea probably occurred following passive airway closure, which in turn caused 
stimulation of mucosal sensory receptors and reflex apnea. (28) 
 
Fig. 3. CPAP Machine and Mask. 
Sleep apnea is not corrected by conventional hemodialysis or peritoneal dialysis. Apnea 
frequency has been reduced by the use of bicarbonate rather than acetate based dialysate 
(29). Intensive daily dialysis has been shown to resolve sleep apnea in one critically ill 
patient (30). Nocturnal Hemodialysis(see glossary) that enables patients to receive 
hemodialysis 6-8 hours per night for 6 nights has been shown to improve sleep apnea (31). 
(Figure 4) Improvements are usually more significant in patients with more severe sleep 
apnea.  
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Fig. 4. Improvement of Sleep Apnea with Nocturnal Hemodialysis. 
Although case reports have indicated correction of sleep apnea after successful kidney 
transplantation (32), preliminary results from case series suggest that sleep apnea resolves 
only in a minority of patients after kidney transplantation (33). The administration of 
branched chain amino acids has shown improvement in apnea index in one patient, 
although the mechanism and implications are not understood. (34). 
10. Restless leg syndrome and periodic limb movement disorder 
Restless leg syndrome (RLS) is a disorder characterized by sensation that usually occurs 
prior to sleep onset and causes an almost irresistible urge to move the legs, resulting in 
delayed sleep onset and disrupted sleep (35). RLS may be idiopathic or secondary to other 
conditions such as pregnancy, rheumatoid arthritis or uremia. Almost 80% of patients with 
RLS also have periodic limb movement disorder (PLMD), a condition characterized by 
episodic limb movements associated with nocturnal awakening and disrupted sleep. 
RLS has been reported in 14-23% in patient on CHD and 20-57% in CKD patients (21, 36). 
The prevalence of PLMD is greater than 50% in CHD and CAPD(see glossary) population (1, 
2, 35-38). RLS has also been reported to be 4.5% in transplanted patients. The prevalence of 
RLS is significantly lower in transplant patients than in patients on maintenance dialysis. 
Declining renal function is associated with increasing prevalence of RLS. 
RLS and PMLD may be equally important as sleep apnea in patients with CKD. RLS 
severity score has been correlated to self perceived sleep problems, nocturnal awakening, 
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delayed sleep onset latency, decreased total sleep time, increased use of sleep medications 
and self reported nocturnal leg movements (36). Polysomnographic studies of dialysis 
patients with RLS and or PLMD showed increase in sleep latency, Stage 1 and Stage 2 sleep, 
and decreased total sleep time and efficiency (38-41). 
11. Pathophysiology 
The pathophysiological mechanisms involved in RLS and PLMD are not very clear. Anemia, 
iron, and vitamin deficiencies, disturbance in peripheral and central nervous system (CNS) 
functioning and musculoskeletal abnormalities have all been proposed. It is likely that 
alteration of dopamine activity in the nervous system plays a role (42-43). 
Correction of anemia by treatment with erythropoietin has been associated with reduction 
in the frequency of PLMD, improvement in sleep quality and day time alertness (44).Iron 
deficiency probably plays a dual role in that it causes anemia and is also a co-factor in the 
metabolism of dopamine in the brain. Treatment with intravenous iron is associated with a 
significant improvement in RLS and PLMD(45).Peripheral neuropathy, secondary to uremia 
or the underlying cause of renal disease such as diabetes may also predispose to develop 
RLS and or PLMD. Data regarding the clinical and laboratory correlation of RLS and PLMD 
is inconsistent. Higher predialysis urea and creatinine levels have been associated with 
increase RLS complaints in one study (1) but no relationship was detected in others (36, 41). 
Higher intact parathyroid hormone(PTH) levels has been found in dialysis patients with 
PLMD vs. those without the disorder(46), but lower levels have been noted in uremic 
patient with RLS in comparison without symptoms(47). 
12. Diagnosis/Clinical significance 
RLS is diagnosed clinically. PLMD is diagnosed objectively with polysomnography, which 
reveals periodic, involuntary movements of the legs during sleep. 
PLMD can be identified on a polysomnogram by examining spiked activity coming from the 
electromyogram (EMG), which measures muscle movement during sleep. Specifically, 
anterior tibialis recording is usually sufficient in detecting the periodic limb movement 
episodes. Periodic limb movements typically last 0.5-5 seconds in duration and usually 
occurs approximately every 20-40seconds. The severity is described in terms of leg 
movement per hour of sleep (periodic limb movement index, PLMI). PLMI >5 is considered 
abnormal. Additionally, the examination of EEG test results will indicate micro-arousals, 
which can also lead to a diagnosis. PLMD can occur independently of RLS, and is more 
common with advancing age (35). RLS is almost always associated with PLMD, but PLMD 
can occur in the absence of RLS. 
RLS is associated with difficulty initiating sleep, poor sleep quality, and impaired health 
quality of life (48) (FIGURE-5). RLS has been associated with depression. PLMD has been 
associated with increased mortality in patient with ESRD (49). 
13. Treatment 
General treatment measures include reducing potential exacerbating factors such as excess 
caffeine, alcohol, nicotine, medical conditions (anemia, iron deficiency), and medications  
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Fig. 5. RLS, Insomnia and quality of life in patients on maintenance dialysis. 
(tricylcic antidepressants, Serotonin reuptake inhibitors, dopamine antagonists). Medical 
therapy includes L-Dopa and dopamine agonists such as pramipexole and ropirinole (64). 
These medications are favored over benzodiazepines. Gabapentin can also be used as 
alternative. The frequency of PLMD is not affected by switching from CHD to NHD (28). 
Kidney transplantation has been associated with an improvement in both RLS and PLMD in 
several small studies (50, 51). 
14. Excessive day time sleepiness 
Excessive day time sleepiness (EDS) has been described in dialysis patients. Seventy-seven 
percent of patients on CAPD reported taking day time naps and 51% reported falling asleep 
unintentionally (46). The Multiple Sleep Latency Test (MSLT) is a sleep disorder diagnostic 
tool. It is used to measure the time elapsed from the start of a daytime nap period to the first 
signs of sleep, called sleep latency. The test is based on the idea that the sleepier people are, 
the faster they will fall asleep. The test consists of four or five 20-minute nap opportunities 
that are scheduled about two hours apart. The test is often performed after an overnight 
sleep study. During the test, data such as the patient's, EEG, muscle activity, and eye 
movements are monitored and recorded. The entire test normally takes about 7 hours.In one 
study, 44 HD patients were studied. Potential subjects with other major chronic conditions 
or those with medications known to have CNS effects were excluded from the study. In 
addition, to exclude those with obvious causes of EDS, subjects with a history suggestive of 
SAS, RLS and PLMD were also excluded. All subjects underwent polysomnography along 
with MSLT. One third of patients of the subjects had MSLT scores consistent with abnormal 
sleepiness (mean sleep latency <8min). High AHI was significantly associated with lower 
MSLT score, but explained only 10% of the variance in MSLT score, suggesting that 
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additional factors play an important role in the expression of day time sleepiness in this 
group (65). 
Benz etal reported the effects of hematocrit normalization with recombinant erythropoietin 
on the sleep of 10 HD patients (44). All subjects underwent an initial nocturnal 
polysomnogram, with seven completing a 40 minutes MWT the next day. Tests were 
repeated after normalization of hematocrit. Treatment resulted in a significant reduction of 
nocturnal periodic limb movements and improvement on the MWT.  
SAS, RLS and PLMD are prevalent in patients with advanced kidney disease and could 
explain EDS, but some studies suggested that other factors related to renal disease or its 
treatment may contribute to EDS (52, 53). 
Mild elevations of BUN and creatinine in renal failure patients have been associated with 
increased slow wave activity in the waking EEG and abnormalities in cognitive function, 
which may explain the susceptibility of patients with advanced renal disease to sleepiness 
(54). Elevation of parathyroid hormone has been associated with increased waking EEG 
slow wave activity in uremic animals and stable dialysis patient (55). The metabolites of 
creatinine may inhibit GABA responses (in mouse neurons) and may interfere with 
neurotransmissions necessary for sleep to occur. These changes may destabilize the 
wakeful state by increasing day time sleepiness propensity and decreasing nocturnal 
sleep (56). 
Treatment with dialysis may also predispose patients to sleepiness. Abnormal production of 
interleukin-1, TNF-alpha, factor S can increase somnolence (57, 58). Rapid removal of these 
sleep inducing substances has also been postulated as the cause for fragmented nocturnal 
sleep and resulting day time sleepiness and fatigue in one study on patients on CAPD (59). 
Dialysis also results in rapid change in electrolytes, acid base balance and serum osmolarity 
which may decrease arousal and alertness (60). Treatment with dialysis may also disrupt the 
circadian pattern sleepiness due to inappropriately timed elevation of serum melatonin in 
response to the hemoconcentration (61) or from change in rhythm of body temperature (62). 
Medications such as antihypertensive and antidepressants may also contribute to the EDS in 
CKD patients. 
15. Summary 
 Sleep complaints and disorders are common in patients with CKD whether on dialysis 
or not and are characterized by difficulty in initiating and maintaining sleep, 
restless/jerking legs, and daytime sleepiness. 
 Polysomnographic studies have demonstrated that dialysis patients have overall 
decreased quantity and quality of sleep, suggesting that behavioral interventions such 
as sleep hygiene and the appropriate use of medications may be helpful. 
 Most common sleep disorders in CKD patients include SAS, RLS, and PLMD. 
 SAS has been effectively treated with CPAP in patients with chronic kidney disease and 
ESRD. Switching from CHD to NHD may also be useful. 
 RLS and PLMD are also very common and are associated increased mortality in 
patients on dialysis. Treatments include correcting anemia, iron deficiency and 
dopamine agonists. 
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 Day time sleepiness is common in patients with ESRD and patients with CKD not on 
dialysis. 
 Sleep disorders have negative impacts on overall quality of life in patients with kidney 
diseases and may affect rehabilitative potential of treatment. 
16. Glossary of dialysis-related terms 
Blood Urea Nitrogen (BUN) is the blood test used to measure nitrogen in the form of Urea, 
which is the by product from protein metabolism produced in liver and removed by kidney 
Dialysate-the fluid used in dialysis, typically with a lower solute concentration than the 
blood, into which metabolic waste and excess electrolytes diffuse. 
Hemodialysis(HD)-a process of removal of fluid and solutes through a semi-permeable 
membrane into dialysate by passing the blood through an artificial kidney. Hemodialysis is 
most commonly delivered to patients three times a week for three to four hours 
(Conventional Hemodialysis-CHD), but may also be given more slowly across the day or 
night (Nocturnal Hemodialysis-NHD). 
Nocturnal Hemodialysis (NHD). Nocturnal hemodialysis or nightly hemodialysis is a form 
of hemodialysis which is done at home by the patient or a family member when the patient 
is sleeping at night. Most patients dialyze five to seven nights a week, anywhere from six 
to12 hours, on average for eight hours. 
Peritoneal Dialysis (PD)-the process of removal of fluid and wastes from the body using the 
semi-permeable membrane of the peritoneum for the diffusion and osmosis, 
Continuous Ambulatory Peritoneal Dialysis (CAPD)-continuous dialysis process that 
involves infusion of fluid into peritoneum, a prolonged dwell period for dialysis and 
drainage. The procedure typically involves four exchanges of fluid daily. 
Kt/V is a way of measuring dialysis adequacy. Kt/V is defined as the dialyzer clearance of 
urea (K, obtained from the manufacturer in mL/min, and periodically measured and 
verified by the dialysis team) multiplied by the duration of the dialysis treatment (t, in 
minutes) divided by the volume of distribution of urea in the body (V, in mL), which is 
approximately equal to the total body water. 
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